NBIX - Neurocrine Biosciences in pact with Sosei for therapies targeting neuropsychiatric disorders

Neurocrine Biosciences (NASDAQ:NBIX) and Sosei Group Corporation (OTCPK:SOLTF) (Sosei Heptares) announced an agreement for strategic collaboration and licensing in the development of muscarinic receptor agonists for neuropsychiatric disorders such as schizophrenia and dementia. Per the deal, Sosei Heptares is eligible to receive an upfront payment of $100M and up to $2.6B of payments based on development, regulatory and commercial milestones. In addition, Tokyo-based biopharma company could receive product royalties at a high single-digit to mid-teen percentage of net sales from the products developed under the partnership. If the deal closes before the year-end, the upfront payment could materially impact its revenue, assuming the recognition of the transaction during Q4 2021, Sosei Heptares said. In return, Neurocrine (NBIX) will receive development and commercialization rights for muscarinic receptor agonists discovered by Sosei. In 2022, the company expects to file an Investigational New Drug (IND) application and begin a Phase 2 trial for the

For further details see:

Neurocrine Biosciences in pact with Sosei for therapies targeting neuropsychiatric disorders